Careteq (ASX:CTQ) Buyback Yield %: 0.00 (As of Jul. 04, 2026)


What is Careteq Buyback Yield %?

Careteq ASX:CTQ Buyback Yield % is 0.00 as of Jul. 04, 2026. The stock has 8 warning signs investors should review. Among 272 Healthcare Providers & Services companies, Careteq ranks worse than 367646.69% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Careteq's current buyback yield was 0.00%.

Careteq Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Careteq's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Careteq Buyback Yield % Chart

Careteq Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
0.00 -55.91 0.00 -82.30 0.00

Careteq Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only -33.20 -82.30 -11.30 0.00 0.00

ASX:CTQ vs VEEV, BTSG, TEM: Buyback Yield % Comparison

For the Health Information Services subindustry, Careteq's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Careteq Buyback Yield % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Careteq's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Careteq's Buyback Yield % falls into.


Careteq Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Careteq's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 2.608309
=0.00%

Careteq's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 2.608309
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Careteq (ASX:CTQ) has a Buyback Yield % of 0.00 as of Jul. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Careteq and its competitors. According to the industry distribution chart, Careteq ranks #999999 out of 272 companies in the Healthcare Providers & Services industry.
Is Careteq's Buyback Yield % too high?
Careteq's current Buyback Yield % is 0.00. Based on the distribution chart, Careteq ranks #999999 out of 272 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Careteq's Buyback Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Careteq ranks #999999 out of 272 companies for Buyback Yield %. This places Careteq in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Careteq and its competitors. Careteq's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Careteq stock overvalued right now?
Based on GuruFocus' analysis, Careteq (ASX:CTQ) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 20% above its estimated fair value. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Careteq (ASX:CTQ), the current Buyback Yield % is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Careteq Business Description

Address 99 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
Careteq Ltd provides Residential Medication Management Review and Home Medicines Review services as part of the Medication Management Programs, generating revenue from medication review, education, and support services. The company focuses on medication management and home care solutions to provide continuity of care and improve clinical outcomes for patients through Home Medication Reviews. Medication-related harm includes adverse drug reactions, medication errors, and complications that jeopardise patient safety and increase healthcare costs. The company operates in Australia.